Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis.
Visceral leishmaniasis is a protozoan disease associated with high fatality rate in developing countries. Although the drug pipeline is constantly improving, available treatments are costly and live-threatening side effects are not uncommon. Moreover, an approved vaccine against human leishmaniasis...
Guardado en:
Autores principales: | Doumet Georges Helou, Aurélie Mauras, François Fasquelle, Juliane Sousa Lanza, Philippe M Loiseau, Didier Betbeder, Sandrine Cojean |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c0f3e4d4ef4340d0a21442226aa11271 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Risk factors for visceral leishmaniasis and asymptomatic Leishmania donovani infection in India and Nepal.
por: Albert Picado, et al.
Publicado: (2014) -
Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis.
por: Pramod K Kushawaha, et al.
Publicado: (2012) -
Comparison of visceral leishmaniasis diagnostic antigens in African and Asian Leishmania donovani reveals extensive diversity and region-specific polymorphisms.
por: Tapan Bhattacharyya, et al.
Publicado: (2013) -
Precision Medicine in Control of Visceral Leishmaniasis Caused by L. donovani
por: Eduard E. Zijlstra
Publicado: (2021) -
Distinct microbiome profiles and biofilms in Leishmania donovani-driven cutaneous leishmaniasis wounds
por: T. D. Jayasena Kaluarachchi, et al.
Publicado: (2021)